News Shire's von Willebrand disease therapy Veyvondi approved in ... The European Commission has approved Shire’s Veyvondi for treatment of the bleeding disorder von Willebrand disease (VWD).
News Shire buys Swiss plasma collection company sanaplasma Shire has bought sanaplasma, a plasma collection company headquartered in Switzerland.
News Shire eyes blockbuster sales as FDA approves HAE therapy The FDA has approved Shire’s first antibody-based preventive treatment for the rare disease hereditary angioedema, raising hopes for blockbuster-level sales as the company prepares for a ta
News Servier expands global footprint post Shire deal Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.
News Roche haemophilia data piles pressure on Shire Hemlibra threatens to take market share from Advate
News Takeda to cut IT, marketing and sales jobs after Shire merge... Takeda aiming for $1.4bn savings per year
News Neuralink gets okay for its first international trial Elon Musk's brain-computer interface (BCI) company Neuralink has been given the green light to test its device in tetraplegic patients in Canada
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
